ATG (Fresenius Biotech)

Phase 2Terminated
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liver Diseases

Conditions

Liver Diseases

Trial Timeline

Jun 1, 2006 → —

About ATG (Fresenius Biotech)

ATG (Fresenius Biotech) is a phase 2 stage product being developed by Astellas Pharma for Liver Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT00436722. Target conditions include Liver Diseases.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00436722Phase 2Terminated

Competing Products

20 competing products in Liver Diseases

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
47
GODEX + PlaceboCelltrionPhase 3
77
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
TacrolimusAstellas PharmaPre-clinical
23
Advagraf + Prograf + PrografAstellas PharmaApproved
85
Prograf + AdvagrafAstellas PharmaApproved
85
ADVAGRAF®Astellas PharmaApproved
85
Prograf + MR4Astellas PharmaPhase 3
77
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
52
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 3
77
Prograf-XL + Prograf + MMFAstellas PharmaPhase 3
77
micafungin + fluconazole + liposomal amphotericin B + caspofunginAstellas PharmaPhase 3
77
Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
85
FK506E (modified release tacrolimus) + Prograf (tacrolimus)Astellas PharmaPhase 3
77
FK778Astellas PharmaPhase 2
52
Tacrolimus modified-release + PrografAstellas PharmaPhase 3
77
Advagraf + PrografAstellas PharmaApproved
85
Prograf + FK506MR capsuleAstellas PharmaPhase 3
77